US20220142978A1 - Use of short chain fatty acids for the treatment and prevention of diseases and disorders - Google Patents

Use of short chain fatty acids for the treatment and prevention of diseases and disorders Download PDF

Info

Publication number
US20220142978A1
US20220142978A1 US17/584,125 US202217584125A US2022142978A1 US 20220142978 A1 US20220142978 A1 US 20220142978A1 US 202217584125 A US202217584125 A US 202217584125A US 2022142978 A1 US2022142978 A1 US 2022142978A1
Authority
US
United States
Prior art keywords
scfa
acid
disease
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/584,125
Other languages
English (en)
Inventor
Alla Arzumanyan
Ira C. Spector
Mark A. Feitelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/903,514 external-priority patent/US11065217B2/en
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Priority to US17/584,125 priority Critical patent/US20220142978A1/en
Publication of US20220142978A1 publication Critical patent/US20220142978A1/en
Priority to US18/901,917 priority patent/US20250017883A1/en
Priority to US18/975,545 priority patent/US20250099410A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the composition of the invention comprises at least one compound comprising a biosynthesis precursor of a SCFA, or a moiety thereof.
  • the biosynthesis precursor, or moiety thereof is selected from the group including, but not limited to an acetyl-CoA carboxylase inhibitor, an adenosine monophosphate kinase (AMPK) activator, vitamin D, and a combination thereof.
  • AMPK adenosine monophosphate kinase
  • an allergic disease includes but is not limited to hay fever, food allergies, atopic dermatitis, allergic asthma, anaphylaxis, and the likes. Symptoms may include red eyes, an itchy rash, runny nose, shortness of breath, or inflammation. Exemplary allergic diseases include, but are not limited to, Food allergies (e.g., milk, soy, eggs, wheat, peanuts, tree nuts, fish, and shellfish), Latex allergies, Allergic rhinitis, Asthma, Atopic eczema, Anaphylaxis, Insect venom, Drug allergies, and any combination thereof. The prevalence of allergic diseases has increased all over the world during the last two decades.
  • Food allergies e.g., milk, soy, eggs, wheat, peanuts, tree nuts, fish, and shellfish
  • Latex allergies e.g., Allergic rhinitis, Asthma, Atopic eczema, Anaphylaxis, Insect venom, Drug allergies, and any combination thereof
  • a composition comprises one or more combinations of SCFAs, salts thereof, biologically active derivatives thereof, or precursors thereof, in combination with at least one other compound.
  • a composition comprises one or more of formic acid, acetic acid, propionic acid, isobutyric acid, butyric acid, tributyrin, N-acetylbutyrate (as well as other forms of butyrate), isovaleric acid, valeric acid, isocaproic acid, caproic acid, lactic acid, succinic acid, pyruvic acid, octanoic acid, and dodecanoic acid.
  • the present invention is also directed to a method of treating or preventing a disease or disorder as described above in combination with one or more additional agents.
  • the immune response in the subject administered the combination of the at least one SCFA, or a molecule comprising a SCFA moiety, and checkpoint inhibitor can be increased by at least about 50%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 650%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, at least about 1200%, at least about 1250%, at least about 1300%, at least about 1350%, at least about 1450%, or at least about 1500%.
  • the method comprises administering to a subject in need thereof a composition comprising at least one SCFA, or a biologically-active derivative or precursor thereof, and additionally one or more DMARD. In one embodiment, the method comprises administering to a subject in need thereof a composition comprising at least one SCFA, or a biologically-active derivative or precursor thereof, in combination with a composition comprising one or more DMARD.
  • the invention also includes a kit comprising compounds useful within the methods of the invention and an instructional material that describes, for instance, the method of administering compositions of the invention as described elsewhere herein.
  • the kit comprises a composition of the invention.
  • Age related macular degeneration causes damage to the macula (a small area in the center of the retina).
  • AMD lipid aggregates
  • drusen lipid aggregates
  • the late stage of dry AMD is characterized by degeneration of retinal pigment epithelium cells and the overlying light-sensing retinal photoreceptors. “There is no way to treat dry AMD.”
  • the Age-Related Eye Disease Studies found that daily intake of high-dose vitamins (vitamins E and C) and minerals (zinc oxide) can slow progression of the disease.
  • choroidal neovascularization occurs (newly immature blood vessels grow toward the outer retina from the underlying choroid).
  • a major advantage of this approach is little to no toxicity relative to other currently available treatments, and at the same time, helping to re-establish gut homeostasis.
  • the models outlined in this Example may not cover all aspects of vasculitis pathogenesis, and for many forms of vasculitis, there is no animal model available. For example, regarding ANCA vasculitis, there is no reproducible model of granulomatous PR3-ANCA. However, the models used can establish proof-of-principle as to whether SCFAs should be taken into human clinical trials against vasculitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transplantation (AREA)
US17/584,125 2017-01-27 2022-01-25 Use of short chain fatty acids for the treatment and prevention of diseases and disorders Pending US20220142978A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/584,125 US20220142978A1 (en) 2017-01-27 2022-01-25 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US18/901,917 US20250017883A1 (en) 2017-01-27 2024-09-30 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US18/975,545 US20250099410A1 (en) 2017-01-27 2024-12-10 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762451192P 2017-01-27 2017-01-27
US201762510867P 2017-05-25 2017-05-25
US201762510872P 2017-05-25 2017-05-25
US201762530371P 2017-07-10 2017-07-10
US201762539572P 2017-08-01 2017-08-01
US201762588961P 2017-11-21 2017-11-21
PCT/US2018/015383 WO2018140687A1 (en) 2017-01-27 2018-01-26 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US15/903,514 US11065217B2 (en) 2017-01-27 2018-02-23 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US17/350,110 US11759442B2 (en) 2017-01-27 2021-06-17 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US17/584,125 US20220142978A1 (en) 2017-01-27 2022-01-25 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/350,110 Continuation US11759442B2 (en) 2017-01-27 2021-06-17 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/901,917 Continuation US20250017883A1 (en) 2017-01-27 2024-09-30 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Publications (1)

Publication Number Publication Date
US20220142978A1 true US20220142978A1 (en) 2022-05-12

Family

ID=62978768

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/584,125 Pending US20220142978A1 (en) 2017-01-27 2022-01-25 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US18/901,917 Pending US20250017883A1 (en) 2017-01-27 2024-09-30 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US18/975,545 Pending US20250099410A1 (en) 2017-01-27 2024-12-10 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
US18/901,917 Pending US20250017883A1 (en) 2017-01-27 2024-09-30 Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US18/975,545 Pending US20250099410A1 (en) 2017-01-27 2024-12-10 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Country Status (5)

Country Link
US (3) US20220142978A1 (https=)
JP (3) JP7161731B2 (https=)
KR (1) KR102646764B1 (https=)
CN (1) CN110475551A (https=)
WO (1) WO2018140687A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115068457A (zh) * 2022-07-04 2022-09-20 南昌大学第一附属医院 短链脂肪酸在制备治疗急性胰腺炎药物中的应用
WO2024102902A1 (en) * 2022-11-10 2024-05-16 Temple University-Of The Commonwealth System Of Higher Education Methods of treating or preventing liver diseases or disorders
WO2024151503A1 (en) * 2023-01-11 2024-07-18 Temple University- Of The Commonwealth System Of Higher Education Treatment of skin disorders with short chain fatty acids
US12226383B1 (en) * 2024-04-30 2025-02-18 Velocity Life Sciences, LLC Compositions containing short-chain fatty acid, methods of use, and methods of making thereof
WO2025207315A1 (en) * 2024-03-25 2025-10-02 Olfactive Ai, Inc. Compositions and methods for treating hypertension by modulating endocrine activity

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
WO2021216548A1 (en) * 2020-04-21 2021-10-28 University Of Massachusetts Methods and compositions for treatment of age-related macular degeneration
FR3111551B1 (fr) * 2020-06-19 2022-08-26 Oreal Composition gélifiée comprenant un sel d’acide gras à chaîne courte
CN111632047A (zh) * 2020-07-27 2020-09-08 上海市中医医院 木犀草素在预防和治疗子宫内膜异位症药物中的应用
US20240009154A1 (en) * 2020-08-04 2024-01-11 Temple University-Of The Commonwealth System Of Higher Education Methods and compositions for treating cytokine release syndrome
JP2023549522A (ja) * 2020-11-12 2023-11-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション がん予防における短鎖脂肪酸の使用
JP2024518421A (ja) * 2021-05-07 2024-05-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キメラ抗原受容体（ｃａｒ）ｔ細胞治療に関連する血清メタボロミクス
CN114767685B (zh) * 2022-04-25 2023-10-20 北京大学第三医院（北京大学第三临床医学院） 四氢叶酸在抑菌或者预防或治疗眼部疾病中的用途
GB202208911D0 (en) * 2022-06-17 2022-08-10 Ravan Bio Limtied Treatments
WO2024100756A1 (ja) * 2022-11-08 2024-05-16 ミヤリサン製薬株式会社 子宮、卵管および卵巣における炎症の予防および／または治療剤
FR3141616A1 (fr) * 2022-11-09 2024-05-10 Pll Therapeutics Principes actifs et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
CN116687899B (zh) * 2023-07-10 2025-03-21 河北医科大学第二医院 短链脂肪酸钠盐丁酸钠和丙酸钠组合用药在als治疗中的应用
CN120093748B (zh) * 2025-03-26 2026-02-06 江汉大学 包含异戊酸和仑伐替尼的组合物在制备抗癌药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150150904A1 (en) * 2012-08-08 2015-06-04 Karen Jane Fischer Dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment
US20160045475A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Methods for the treatment of diseases ameliorated by pde4 inhibition using dosage titration of apremilast

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
JP2000072667A (ja) 1998-08-25 2000-03-07 Kurasuraa:Kk 大腸炎治療用経口投与剤
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20080153908A1 (en) * 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
CN101959429B (zh) * 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
US9339667B2 (en) * 2009-02-18 2016-05-17 Sea Qiq As Mixture of inorganic compounds, preparations containing the mixture and use of the mixture
US8962686B2 (en) * 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
MX2013001190A (es) * 2010-07-29 2013-03-18 Cosmo Technologies Ltd Composiciones farmaceuticas y/o dieteticas con base en acidos grasos de cadena corta.
WO2012131069A1 (en) 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
WO2015006355A2 (en) * 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150150904A1 (en) * 2012-08-08 2015-06-04 Karen Jane Fischer Dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like and method of treatment
US20160045475A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Methods for the treatment of diseases ameliorated by pde4 inhibition using dosage titration of apremilast

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115068457A (zh) * 2022-07-04 2022-09-20 南昌大学第一附属医院 短链脂肪酸在制备治疗急性胰腺炎药物中的应用
WO2024102902A1 (en) * 2022-11-10 2024-05-16 Temple University-Of The Commonwealth System Of Higher Education Methods of treating or preventing liver diseases or disorders
WO2024151503A1 (en) * 2023-01-11 2024-07-18 Temple University- Of The Commonwealth System Of Higher Education Treatment of skin disorders with short chain fatty acids
WO2025207315A1 (en) * 2024-03-25 2025-10-02 Olfactive Ai, Inc. Compositions and methods for treating hypertension by modulating endocrine activity
US12226383B1 (en) * 2024-04-30 2025-02-18 Velocity Life Sciences, LLC Compositions containing short-chain fatty acid, methods of use, and methods of making thereof
US12485101B2 (en) 2024-04-30 2025-12-02 Velocity Life Sciences, LLC Compositions containing short-chain fatty acid, methods of use, and methods of making thereof

Also Published As

Publication number Publication date
KR20190108144A (ko) 2019-09-23
CN110475551A (zh) 2019-11-19
JP2020505471A (ja) 2020-02-20
JP7688360B2 (ja) 2025-06-04
KR102646764B1 (ko) 2024-03-13
US20250017883A1 (en) 2025-01-16
WO2018140687A1 (en) 2018-08-02
JP7161731B2 (ja) 2022-10-27
US20250099410A1 (en) 2025-03-27
JP2022179617A (ja) 2022-12-02
JP2025069304A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
US11759442B2 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US20250099410A1 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US11963938B2 (en) Use of short chain fatty acids in cancer prevention
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
CA3159711A1 (en) Designed bacterial compositions and uses thereof
WO2023114445A1 (en) Prevention of bone loss
WO2015085351A1 (en) Pharmaconutrient composition
EP3573612A1 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
KR20250107214A (ko) 간질환 또는 간장애의 치료 또는 예방 방법
HK40082664A (en) Use of short chain fatty acids in cancer prevention
CA2974510C (en) Use of short chain fatty acids in cancer prevention

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED